The CARTITUDE-4 trial shows that how well patients respond to bridging therapy — treatment given while waiting for CAR T-cell manufacturing — strongly affects how well cilta-cel (Carvykti) works in relapsed or refractory multiple myeloma. Patients whose disease improved or stayed stable during this waiting period had much better survival and fewer serious side effects […]
Researchers have developed a new platform called the Cancer-Selective modRNA Translation System (cSMRTS), which allows mRNA therapies to work only in cancer cells while avoiding healthy tissue. The system uses a dual mRNA “on/off” circuit based on microRNA patterns. In healthy cells, a sensor mRNA blocks the treatment. In cancer cells, tumor-specific microRNAs disable the
New mRNA Technology Targets Cancer Cells While Sparing Healthy Tissue Read More »
The final results of the Phase 2 MOUNTAINEER trial confirm that the combination of tucatinib (Tukysa) and trastuzumab (Herceptin) provides lasting benefit with manageable side effects for patients with HER2-positive, RAS wild-type metastatic colorectal cancer. After a median follow-up of 32.4 months, the confirmed overall response rate was 39.3%. Median overall survival reached 23.9 months,
The European Medicines Agency (EMA) has recommended approval of retifanlimab (Zynyz) combined with carboplatin and paclitaxel as a first-line treatment for adults with metastatic or inoperable recurrent squamous cell carcinoma of the anal canal. The recommendation is based on results from the phase 3 POD1UM-303 trial. Patients who received retifanlimab plus chemotherapy had better outcomes
Researchers have identified a key molecular switch that controls how aggressive pancreatic ductal adenocarcinoma becomes and how it responds to treatment. The study shows that mutant KRAS, the main driver of pancreatic cancer, suppresses GATA6, a gene that helps cancer cells stay more mature and treatment-responsive. When GATA6 is turned off, tumors shift into a
New Study Identifies Molecular Switch Driving Aggressive Pancreatic Cancer Read More »
A new study found that starting patients on a lower dose of enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) can improve tolerability without reducing survival in advanced urothelial carcinoma. Researchers analyzed data from 496 patients treated with this first-line combination and compared standard dosing with lower starting doses. Patients who began at a reduced dose had fewer
The FDA has given Fast Track designation to pelareorep (Reolysin), an intravenous oncolytic virus therapy, for second-line treatment of patients with KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The therapy is used in combination with standard treatment, bevacizumab plus FOLFIRI. The decision is based on Phase 1 trial data showing strong improvements compared with historical standard care.
FDA Grants Fast Track Status to Pelareorep for KRAS-Mutant Metastatic Colorectal Cancer Read More »
Scientists have mapped all possible mutations in a key region of the CTNNB1 gene that controls the cancer-related protein β-catenin. Normally, this region tells the cell to break down β-catenin, but mutations allow it to build up and drive tumor growth. Using genome-editing tools in mouse stem cells, researchers tested 342 different mutations and found
New Mutation Map Reveals How CTNNB1 Drives Cancer Growth and Treatment Response Read More »
A phase 1/2 study evaluated tagraxofusp (Elzonris), a CD123-targeted therapy, as a single-agent treatment for patients with myelofibrosis. The drug showed modest clinical benefit but was generally well tolerated, with no dose-limiting toxicities reported. These findings suggest tagraxofusp may be better suited for use in combination with other therapies rather than as a standalone treatment.
Tagraxofusp Shows Modest Activity and Favorable Safety in Myelofibrosis Trial Read More »
The FDA has accepted a supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who cannot receive immunotherapy. A regulatory decision is expected in the second quarter of 2026. The application is supported by Phase 3 TROPION-Breast02 trial results showing that Dato-DXd outperformed
FDA Reviews Dato-DXd as First-Line Option for Advanced Triple-Negative Breast Cancer Read More »